Despite that these results suggest that infigratinib has activity in cholangiocarcinoma harboring FGFR2 fusions previously treated with systemic therapy, the discontinuation of the development of infigratinib precludes the implementation of the agent in first-line treatment. This evidence concerns the gene FGFR2 and cholangiocarcinoma.